Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib PK, Safety, and Efficacy in Chinese Patients with Advanced Solid Tumors
NCT02398513Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in solid tumor, sponsored by Bayer. Primary endpoints: Maximum Drug Concentration in Plasma, Area Under the Curve (0-24h) and 3 more. Started Apr 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02398513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398513.